194 related articles for article (PubMed ID: 12432437)
1. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease.
Lerner G; Kale AS; Warady BA; Jabs K; Bunchman TE; Heatherington A; Olson K; Messer-Mann L; Maroni BJ
Pediatr Nephrol; 2002 Nov; 17(11):933-7. PubMed ID: 12432437
[TBL] [Abstract][Full Text] [Related]
2. Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis.
Doshi S; Chow A; Pérez Ruixo JJ
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):75S-90S. PubMed ID: 20881221
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.
Allon M; Kleinman K; Walczyk M; Kaupke C; Messer-Mann L; Olson K; Heatherington AC; Maroni BJ
Clin Pharmacol Ther; 2002 Nov; 72(5):546-55. PubMed ID: 12426518
[TBL] [Abstract][Full Text] [Related]
5. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
[TBL] [Abstract][Full Text] [Related]
6. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis.
Padhi D; Ni L; Cooke B; Marino R; Jang G
Clin Pharmacokinet; 2006; 45(5):503-10. PubMed ID: 16640455
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa.
Aarup M; Bryndum J; Dieperink H; Joffe P
Nephrol Dial Transplant; 2006 May; 21(5):1312-6. PubMed ID: 16396971
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia.
Blumer J; Berg S; Adamson PC; Loew T; Rossi G; Hastings C
Pediatr Blood Cancer; 2007 Oct; 49(5):687-93. PubMed ID: 17120240
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy.
Heatherington AC; Dittrich C; Sullivan JT; Rossi G; Schueller J
Clin Pharmacokinet; 2006; 45(2):199-211. PubMed ID: 16485917
[TBL] [Abstract][Full Text] [Related]
10. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
11. [Darbepoetin-alfa treatment of anemia secondary to chronic renal failure in dialysis patients: Results of a French multicenter study].
Kessler M; Hannedouche T; Fitte H; Cayotte JL; Urena P; Réglier JC;
Nephrol Ther; 2006 Sep; 2(4):191-9. PubMed ID: 16966064
[TBL] [Abstract][Full Text] [Related]
12. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
13. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
Joy MS
Ann Pharmacother; 2002; 36(7-8):1183-92. PubMed ID: 12086553
[TBL] [Abstract][Full Text] [Related]
14. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
[TBL] [Abstract][Full Text] [Related]
15. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of darbepoetin alfa.
Macdougall IC; Padhi D; Jang G
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv2-iv9. PubMed ID: 17526547
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
19. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
20. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients.
Mahajan S; Boulton H; Gokal R
J Nephrol; 2004; 17(5):687-92. PubMed ID: 15593036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
